Bladder cancer is a cancer that forms in tissues ... duplication and immune exhaustion with tumor progression. Detecting FGFR3-mutant muscle-invasive and metastatic urothelial cancers (MIBC ...

Tyra Biosciences, Inc. (NASDAQ: TYRA) shares decreased in price Friday. The Carlsbad, Calif.-based Tyra, a clinical-stage biotechnology company focused on developing next-generation precision ...

PR Newswire NEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The global premature ejaculation treatment market size is estimated to grow by USD 1.53 billion from 2025 to 2029, according ...

1Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. 2Department of Oncology, National Taiwan University Biomedical Park Hospital, Hsinchu, Taiwan. 3Graduate Institute of ...

Pathogenic activating mutations in the fibroblast growth factor receptor 3 (FGFR3) drive disease maintenance and progression in urothelial cancer. 10-15% of muscle-invasive and metastatic urothelial ...

The EdgeFlow UH10 bladder scanner and RenaFlex ureteroscope system received FDA clearance ... for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with ...

According to GlobalData, Phase II drugs for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer ... of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) ...

“Our study highlights the potential of epigenomic profiling from a simple blood draw to provide a real-time, non-invasive readout of PSMA expression that corresponds with treatment response," says ...

Bladder control problems, or urinary incontinence, can cause an uncontrolled urgency to urinate, increased visits to the bathroom, and accidental leakage. Different medical conditions, aging, and ...

In the FGFR3+ mUC subpopulation who received > 90mg ... a Phase 2 study on TYRA-300 in the treatment of non-muscle invasive bladder cancer sometime in 2025. As for genetic indications, TYRA ...